Strategies for reversing drug resistance (Q35567287)

8 August 2017

1 reference

title

Strategies for reversing drug resistance (English)

1 reference

antineoplastic resistance

8 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576855

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

24 March 2024

1

Tito Fojo

1 reference

8 August 2017

Susan Bates

2

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

8 August 2017

20 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576855

full work available at URL

24 March 2024

https://www.nature.com/articles/1206951.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

https://www.nature.com/articles/1206951

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

24 March 2024

1 reference

8 August 2017

22

1 reference

8 August 2017

7512-7523

1 reference

8 August 2017

47

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206951

8 August 2017

0 references

cites work

The Bcl-2 protein family: arbiters of cell survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Therapeutic cancer targeting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Inhibitors of multidrug resistance to antitumor agents (MDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

ABC transporters in lipid transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Induction of the growth inhibitor IGF-binding protein 3 by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Structural and biochemical basis of apoptotic activation by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Pharmacokinetics of vincristine in cancer patients treated with nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

mtCLIC/CLIC4, an organellular chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Clinical trials of P-glycoprotein reversal in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Pharmacological considerations in the modulation of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Interactions of antimitotic peptides and depsipeptides with tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Structural, mechanistic and clinical aspects of MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Dependence of transcriptional repression on CpG methylation density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

The effect of verapamil on the pharmacokinetics of adriamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A model for p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

21 January 2018

Mechanisms of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Antisense therapy in oncology: new hope for an old idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Development of resistance to glutathione depletion-induced cell death in CC531 colon carcinoma cells: association with increased expression of bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

An information-intensive approach to the molecular pharmacology of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

PUMA induces the rapid apoptosis of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

A family of drug transporters: the multidrug resistance-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Clinical studies with modulators of multidrug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Pharmacological rescue of mutant p53 conformation and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Serum can inhibit reversal of multidrug resistance by chemosensitisers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

Cretaceous age for the feathered dinosaurs of Liaoning, China

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206951

7 January 2021

L-S,R-buthionine sulfoximine: historical development and clinical issues

6

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein

24 March 2024

11

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells

24 March 2024

14

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells

24 March 2024

26

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells

24 March 2024

32

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)

24 March 2024

55

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines

24 March 2024

74

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

24 March 2024

91

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

24 March 2024

111

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

24 March 2024

125

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206951

24 March 2024

Identifiers

1 reference

8 August 2017

1 reference